Agios Pharmaceuticals Inc Webinar on Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook Transcript
Good morning, everybody. Hello, hi out there. Thanks for joining us this morning. Apologies to those of you on the West Coast for the early hour this morning, but we appreciate your participation in our first ever pyruvate kinase-R activation webinar here at AGIOS. So I'm Jackie Fouse, the CEO. I'm going to go through the agenda in just 1 second. I'm obliged to remind you of our forward-looking statements. So there they are on the screen.
Here's our exciting agenda this morning. I will make a few brief opening remarks, and then very pleased to have Dr. van Beers with us this morning, an investigator we've worked with at Agios for quite some time, and I'll show you a snapshot of his biography in just a moment. Our Chief Scientific Officer, Bruce Car, will speak about the biology of PKR activation. Bruce has been with us for about a year now at Agios. Very happy to have him in the team. Many of you know, Dr. Chris Bowden, our Chief Medical Officer. He'll go through our clinical programs and the data that we've generated so far
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
